glp 1 melts GLP-1 friendly innovations on the upswing GLP-1 with Vitamin B12 |

Overlap with pramlintide

According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on formulation and dose) Vomiting (524% of patients) Diarrhea (830% of patients) Abdominal pain (511% of patients) Constipation (324% of patients) These gastrointestinal symptoms typically emerge during dose escalation and often diminish over time as physiological tolerance develops

Barry Conrad Oh my god, it's a long time

For glioblastoma (GBM), a blood-brain barrier-penetrating delivery system was developed using Angiopep-2/TAT peptide-modified extracellular vesicles (EVs) to transport Cas9/sgRNA complexes targeting glutathione synthetase (GSS)